Literature DB >> 9426061

Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP.

M Marcelli1, G R Cunningham, S J Haidacher, S J Padayatty, L Sturgis, C Kagan, L Denner.   

Abstract

The goals of this work were to establish a reproducible and effective model of apoptosis in a cell line derived from advanced prostate cancer and to study the role of the caspase family of proteases in mediating apoptosis in this system. The study involved the use of the prostate cancer cell line LNCaP. Apoptosis was induced using the hydroxymethyl glutaryl CoA reductase inhibitor, lovastatin, and was evaluated by agarose gel electrophoresis of genomic DNA, morphological criteria, and terminal deoxynucleotidyl transferase-mediated nick end labeling. Caspases were studied by catalytic activity, mRNA induction, and protein processing. Lovastatin (30 microM) was an effective inducer of apoptosis, causing changes that were evident after 48 h and essentially complete after 96-120 h of treatment. These effects were prevented by the simultaneous addition of mevalonate (300 microM) to the culture medium. Lovastatin induced a proteolytic activity that was able to cleave the enzyme poly(ADP-ribose) polymerase and the substrate Z-DEVD-AFC, which is modeled after the P1-P4 amino acids of the poly(ADP-ribose) polymerase cleavage site. Caspase-7, but not caspase-3, underwent proteolytic activation during lovastatin-induced apoptosis, an effect prevented by mevalonate. Caspase-7 was the only detected interleukin 1beta converting enzyme family protease with DEVD cleavage activity that exhibited lovastatin-induced mRNA up-regulation. Again, mevalonate blocked this effect. Lovastatin-induced apoptosis also was prevented when the caspase inhibitors Z-DEVD-CH2F or Z-VAD-CH2F (100 microM) where added to the medium. These studies have identified lovastatin as a powerful inducer of apoptosis in the cell line LNCaP. Caspase activation was a necessary event for LNCaP cells to undergo apoptosis during treatment with lovastatin. Of the caspases tested, only caspase-7 underwent proteolytic activation after stimulation with lovastatin. Identification of caspase-7 as a potential mediator of lovastatin-induced apoptosis broadens our knowledge of the molecular events associated with programmed cell death in a cell line derived from prostatic epithelium.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.

Authors:  Jason B Garrison; Natasha Kyprianou
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 2.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

Review 3.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

4.  Effects of statins on the risk of hepatocellular carcinoma.

Authors:  Pejman G Mansourian; Masato Yoneda; M Krishna Rao; Fernando J Martinez; Emmanuel Thomas; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

Review 5.  The effect of statins on cancer cells--review.

Authors:  Lucyna Matusewicz; Justyna Meissner; Monika Toporkiewicz; Aleksander F Sikorski
Journal:  Tumour Biol       Date:  2015-05-23

6.  Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.

Authors:  G Pelaia; L Gallelli; T Renda; D Fratto; D Falcone; M Caraglia; M T Busceti; R Terracciano; A Vatrella; R Maselli; R Savino
Journal:  Cell Prolif       Date:  2012-10-10       Impact factor: 6.831

7.  PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines.

Authors:  Michele Salemi; Rosita A Condorelli; Sandro La Vignera; Nunziata Barone; Federico Ridolfo; Maria C Giuffrida; Enzo Vicari; Aldo E Calogero
Journal:  Hum Cell       Date:  2014-07-19       Impact factor: 4.174

8.  Leucine zipper, down regulated in cancer-1 gene expression in prostate cancer.

Authors:  Michele Salemi; Nunziata Barone; Sandro La Vignera; Rosita A Condorelli; Domenico Recupero; Antonio Galia; Filippo Fraggetta; Anna Maria Aiello; Pietro Pepe; Roberto Castiglione; Enzo Vicari; Aldo E Calogero
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

Review 9.  Rationale for statins in the chemoprevention of prostate cancer.

Authors:  Robert J Hamilton; Stephen J Freedland
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

10.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.